NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP is investigating Galectin Therapeutics Inc. (NasdaqCM:GALT) (“Galectin” or the “Company”) in connection with possible violations of federal securities laws.
To get more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt. There is no cost or obligation to you.
On July 28, 2014, an article featured on TheStreet.com noted that Galectin hired a stock promotions firm known as Emerging Growth Corp. to tout its stock. The article further notes that Emerging Growth “describes itself as an investor relations and marketing company, but that it’s just a shiny façade on what is really an ugly penny-stock promotions scheme.” The following day Galectin reported disappointing results regarding its phase 1 experimental drug trial for GR-MD-02.
If you own common stock in Galectin and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/galectin-therapeutics-galt.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.